Compare Harley-Davidson Inc (HOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Novo Nordisk A/S — how do they compare? Harley-Davidson Inc trades at $26.75 (market cap $2.78B), while Novo Nordisk A/S trades at $38.05 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 59.5× Harley-Davidson Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and Novo Nordisk A/S for 116 Days on average.
| HOG | NVO | |
|---|---|---|
Market Cap | $2.78B | $165.31B |
Volume | 2,966,389 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $63.98 |
52-Week Low | $17.19 | $35.29 |
Typical Hold Time | 91 Days | 116 Days |
Enterprise Value | $3.20B | $179.56B |
Dividend Yield | 2.8% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $28.50. Recent Q2 2026 earnings beat expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 7.57%. The company maintains a dividend and shows improved cash flow trends, though it faces headwinds from tariffs and a recent data breach investigation.
The stock presents a mixed outlook: valuation metrics like P/E of 14.97 and P/B of 0.9 suggest potential upside, but declining profitability and competitive pressures pose risks. Investor sentiment is cautious with 61% hold ratings, while institutional activity shows mixed positioning. Key catalysts include execution of the 'Back to the Bricks' strategy, though tariff exposures and softening demand remain concerns.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
